FAACT's Roundtable

Ep. 27: OIT Must-Knows and Learning About Palforzia with Dr. Brian Vickery

July 22, 2020
FAACT's Roundtable
Ep. 27: OIT Must-Knows and Learning About Palforzia with Dr. Brian Vickery
Chapters
FAACT's Roundtable
Ep. 27: OIT Must-Knows and Learning About Palforzia with Dr. Brian Vickery
Jul 22, 2020

Ep. 27: In this episode, we take a very straightforward and deep dive into the world of Oral Immunotherapy (OIT) with board-certified allergist, Dr. Brian Vickery, who also demystifies the new peanut food allergy drug named Palforzia. In this very candid discussion, listeners will discover information to help their own conversations with their doctors to determine if OIT might be an appropriate choice for their family.

To keep you in the know, below are helpful links:

Visit us at www.FoodAllergyAwareness.org and follow us on Facebook, Twitter, Instagram, LinkedIn, Pinterest, and YouTube. Contact us directly via Email.

Dr. Brian P. Vickery, MD
Associate Professor of Pediatrics
Director, Food Allergy Center at Emory+Children’s

Dr. Brian Vickery is an Associate Professor of Pediatrics at Emory University and Director of the Food Allergy Center at Children's Healthcare of Atlanta. For 12 years he has led productive and consistently funded patient-oriented research teams developing therapies for IgE-mediated food allergies, work spanning murine models to Phase 3 trials. With the first new therapies poised for FDA approval and translation into clinical care, he is now particularly interested in the intersection of translational and outcomes research in generating rational, evidence-driven treatment strategies that maximize the benefit/risk relationship and improve patient-centered outcomes. 

Dr. Vickery completed his undergraduate work at the University of Georgia and then obtained his medical degree from the Medical College of Georgia. He completed his pediatric residency and chief residency at New York-Presbyterian Hospital/Weill Cornell Medical Center, and his fellowship training in allergy & clinical immunology at Yale University School of Medicine, where he worked on a preclinical model of the investigational peanut allergy vaccine EMP-123 in the laboratory of Dr. Kim Bottomly. His junior faculty years were spent at Duke University School of Medicine and the University of North Carolina School of Medicine, as an NIH-funded researcher and the Director of the UNC Food Allergy Initiative under the mentorship of Dr. Wesley Burks. 

Dr. Vickery has published over 50 papers in leading journals such as the New England Journal of Medicine, JACI, and Science Translational Medicine, has contributed to the development of national food allergy treatment guidelines, and has a current h-index of 37. He currently serves as Vice-Chair, Adverse Reactions to Foods Committee (AAAAI) and Chief Medical Advisor for Patient Experience and Outcomes Research Advisory Board (FARE). He is committed to developing the careers of the next generation of clinicians and researchers in allergy.

Show Notes

Ep. 27: In this episode, we take a very straightforward and deep dive into the world of Oral Immunotherapy (OIT) with board-certified allergist, Dr. Brian Vickery, who also demystifies the new peanut food allergy drug named Palforzia. In this very candid discussion, listeners will discover information to help their own conversations with their doctors to determine if OIT might be an appropriate choice for their family.

To keep you in the know, below are helpful links:

Visit us at www.FoodAllergyAwareness.org and follow us on Facebook, Twitter, Instagram, LinkedIn, Pinterest, and YouTube. Contact us directly via Email.

Dr. Brian P. Vickery, MD
Associate Professor of Pediatrics
Director, Food Allergy Center at Emory+Children’s

Dr. Brian Vickery is an Associate Professor of Pediatrics at Emory University and Director of the Food Allergy Center at Children's Healthcare of Atlanta. For 12 years he has led productive and consistently funded patient-oriented research teams developing therapies for IgE-mediated food allergies, work spanning murine models to Phase 3 trials. With the first new therapies poised for FDA approval and translation into clinical care, he is now particularly interested in the intersection of translational and outcomes research in generating rational, evidence-driven treatment strategies that maximize the benefit/risk relationship and improve patient-centered outcomes. 

Dr. Vickery completed his undergraduate work at the University of Georgia and then obtained his medical degree from the Medical College of Georgia. He completed his pediatric residency and chief residency at New York-Presbyterian Hospital/Weill Cornell Medical Center, and his fellowship training in allergy & clinical immunology at Yale University School of Medicine, where he worked on a preclinical model of the investigational peanut allergy vaccine EMP-123 in the laboratory of Dr. Kim Bottomly. His junior faculty years were spent at Duke University School of Medicine and the University of North Carolina School of Medicine, as an NIH-funded researcher and the Director of the UNC Food Allergy Initiative under the mentorship of Dr. Wesley Burks. 

Dr. Vickery has published over 50 papers in leading journals such as the New England Journal of Medicine, JACI, and Science Translational Medicine, has contributed to the development of national food allergy treatment guidelines, and has a current h-index of 37. He currently serves as Vice-Chair, Adverse Reactions to Foods Committee (AAAAI) and Chief Medical Advisor for Patient Experience and Outcomes Research Advisory Board (FARE). He is committed to developing the careers of the next generation of clinicians and researchers in allergy.